Brief: Akari Therapeutics' Preclinical Data Demonstrates The Potential Of Its Novel ADC Spliceosome Modulating Payload, Ph1
24/09/2025 14:41
Sept 24 (Reuters) - Akari Therapeutics PLC AKTX.O: AKARI THERAPEUTICS’ PRECLINICAL DATA DEMONSTRATES THE POTENTIAL OF ITS NOVEL ADC SPLICEOSOME MODULATING PAYLOAD, PH1 AKARI : PLANS TO TEST AGAINST DIFFERENT PROSTATE CANCER TARGETS THE HYPOTHESIS THAT ARPI PLUS PH1 ADCS MAY SLOW DEVELOPMENT OF RESISTANCE Source text: ID:nGNX9td05g Further company coverage: AKTX.O
Recent news on Akari Therapeutics
See all newsBrief: Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models
UK's Akari Therapeutics Q2 net loss widens on higher R&D for AKTX-101
Akari Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Akari Therapeutics PLC expected to post a loss of $1.40 a share - Earnings Preview
Brief: Akari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics